101 Montgomery Street
About Audentes TherapeuticsAudentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of gene therapy technology.
The company consists of a focused, experienced, and passionate team driven by the goal of improving the lives of patients. We take pride in strong, global relationships with the patient, research, and medical communities.
130 articles with Audentes Therapeutics
Audentes Therapeutics, an Astellas Company, today announced that it is expanding its mission to develop potentially life-changing genetic medicines by becoming Astellas Gene Therapies.
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
The agency placed the hold on the Astellas company’s trial after two patients died in the trial.
Audentes Therapeutics Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy (XLMTM)
Audentes Therapeutics , an Astellas genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold for the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy (XLMTM). XLMTM is a serious, life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure, and early death. “We are grateful for t
8/24/2020It was a relatively quiet week for clinical trial news. Here’s a look.
Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-linked Myotubular Myopathy
Audentes Therapeutics, Inc., an Astellas company, announced that a third study patient has passed away in the ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy, which is a serious, life-threatening neuromuscular disease characterized by extreme muscle weakness, respiratory failure, and early death.
The trial remains on clinical hold and continues to indefinitely delay the company’s plans to seek regulatory approval for the treatment.
7/6/2020Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
San Francisco-based Audentes Therapeutics reported two deaths in its gene therapy clinical trial. The therapy, AT132, is for X-linked myotubular myopathy.
Audentes Therapeutics, Inc., an Astellas genetic medicines company, announced that it has appointed Julie Person as Senior Vice President, Human Resources.
It is planned to go into operation in 2021, and is expected to create more than 200 new jobs in Lee County, North Carolina.
Audentes Therapeutics Announces Plans to Build New State-of-the-Art Gene Therapy Manufacturing Facility in Sanford, North Carolina
Audentes Therapeutics, an Astellas company focused on developing innovative AAV-based genetic medicines, announced today that it plans to invest $109 million to build a new 135,000 square foot, state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina
Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas' newly created Genetic Regulation Primary Focus
The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.
Astellas Pharma Inc. and Audentes Therapeutics, Inc., announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3 billion..
Continued progress in Pompe Disease, DMD and DM1 pipeline programs: AT845 IND submitted and clinical start-up activities underway; AT702 IND on track for first quarter 2020 submission
Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019
Audentes Therapeutics, Inc., a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019.
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society
Continued significant and durable improvements in respiratory function and developmental motor milestones in all treated patients
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct. 4, 2019
Audentes Therapeutics, Inc. announced it has granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to twenty-one individuals hired by Audentes in September 2019.
Audentes Therapeutics, Inc. announced that Natalie Holles, President and Chief Operating Officer, will participate in the following investor conferences in October